Category Research

MAIA Biotech’s Latest Advancements: Yearly Success and Breakthroughs in Cancer Treatment

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, has announced its highlights and key achievements for the year so far, along with recent clinical progress regarding its lead candidate, THIO. THIO…

Read MoreMAIA Biotech’s Latest Advancements: Yearly Success and Breakthroughs in Cancer Treatment

Dr. Michael Donovan to Lead Personalized Cancer Therapy at Cellworks’ New CLIA Lab

A leader in Personalized Therapy Decision Support and Precision Drug Development, Cellworks, has announced the opening of a CLIA-certified computational laboratory in Franklin, Tennessee. Administered by the Centers for Medicare and Medicaid Services, CLIA (Clinical Laboratory Improvement Amendments) ensures high…

Read MoreDr. Michael Donovan to Lead Personalized Cancer Therapy at Cellworks’ New CLIA Lab

Upneeq® Clinches 2024 Shape Skin Award for ‘Best Lift’ in the Professional Treatment Category

RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition, naming Upneeq® as “Best for Lift” in the professional category,…

Read MoreUpneeq® Clinches 2024 Shape Skin Award for ‘Best Lift’ in the Professional Treatment Category

Gate Neurosciences to Present New Synaptic Function Molecule Research at 2024 ASCP Annual Meeting

A clinical-stage biotechnology company focused on precision medicine to develop next-generation neuroscience therapies announced its upcoming activities at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami Beach, FL, from May 28-31, 2024. The company…

Read MoreGate Neurosciences to Present New Synaptic Function Molecule Research at 2024 ASCP Annual Meeting

AC Immune and Takeda Enter Exclusive License Agreement for Amyloid Beta Immunotherapy in Alzheimer’s Disease

Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for Alzheimer’s disease treatment. ACI-24.060 is an anti-Abeta active…

Read MoreAC Immune and Takeda Enter Exclusive License Agreement for Amyloid Beta Immunotherapy in Alzheimer’s Disease

Be Biopharma Unveils Promising Preclinical Data on Novel B Cell Treatment for Hypophosphatasia

Be Biopharma, Inc. (“Be Bio”), a trailblazing company in the development of Engineered B Cell Medicines (BCMs), unveiled new preclinical findings today, showcasing the production of active ALP by a BCM. This breakthrough underscores BCMs’ potential as a treatment avenue…

Read MoreBe Biopharma Unveils Promising Preclinical Data on Novel B Cell Treatment for Hypophosphatasia